Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders

 Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders

Shots:

  • The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised its option to initiate a fourth program based on the results from three initial programs
  • Following the Mar’2020 agreement, Codexis has created the novel enzyme sequences to advance gene therapies into pre-clinical development by utilizing its CodeEvolver protein engineering platform
  • Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products emerges from the collaboration

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: GeneOnline

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post